Abstract

Aditya Zade73576*

This work encompasses a comprehensive review and investigative study with the objective of advancing Tuberculosis (TB) drug development. The primary aims are structured to provide a nuanced understanding of TB drug efficacy, resistance mechanisms, and the optimization of treatment regimens. Aim involves a critical examination of the effectiveness of existing TB drugs against diverse strains of Mycobacterium tuberculosis ( M. tuberculosis)>, including assessments of treatment success rates, relapse occurrences and the emergence of drug resistance. By scrutinizing the performance and limitations of current treatments, this aim seeks to provide a foundational understanding for subsequent research endeavors. Next, we focus on identifying and evaluating potential new drug candidates for TB treatment. This includes a thorough exploration of the mechanisms of action and potential synergies of novel compounds. We contributed to the development of an innovative drug pipeline capable of overcoming the challenges posed by drug-resistant TB strains. Further, we concentrate on molecular intricacies underlying drug resistance in M. tuberculosis. This includes the characterization of genetic mutations associated with resistance to commonly used antitubercular drugs. By deciphering the genetic situation of drug resistance, this aims to inform targeted strategies for addressing and preventing resistance, fortifying the arsenal against TB. Subsequently, we intended to develop optimized TB treatment regimens by scrutinizing the pharmacokinetics and pharmacodynamics of both existing and novel TB drugs. Investigation into the potential for combination therapies to enhance treatment outcomes is a key component. By optimizing drug regimens, we seek to streamline TB treatment protocols, making them more effective, patient-friendly, and adaptable to the evolving condition of the disease. The outlined objectives provide an overview for achieving the predominant aims of the study. From conducting a thorough literature review to screening potential drug candidates, characterizing drug resistance, and assessing drug interactions, each objective serves as a critical building block in the collective pursuit of advancing TB drug development. This theoretical abstract highlights the significance of a multidimensional approach to TB drug development, emphasizing the synergistic integration of literature review, drug screening, genomic analysis, and pharmacological studies. Through meticulous investigation, the research aspires to contribute theoretical frameworks, methodologies, and insights that can propel the field forward, ultimately leading to more efficacious and consider treatments for TB.